Cancer is a growing initiative that is recognized at the federal level. Last year President Obama introduced a renewed effort for oncology with Cancer Moonshot. The goal of this initiative is to improve the progress of cancer research and accelerate the way that supporters can achieve research and treatment success. This is a large and admirable objective that is based on the way that researchers and institutions can work alongside industry in order to create sustainable solutions in the field of cancer research.
Overcoming obstacles within the healthcare system will help diagnosis and the way that drugs are discovered. Public funding as well as private philanthropic support is important to achieve these outcomes. By continuing research and involving large amounts of data, it is possible for ideas and findings to be incorporated into new treatment goals and outcomes.
There are also challenges to institutionalization which will need to be overcome. Some examples include the incorporation of new technology in highly regulated infrastructure. It can often take time to adopt new systems and innovations within industries such as healthcare, because of regulations regarding implementing change.
Cancer research has been significantly affected by these standards because of the slow incorporation of technological advancements. Involving information technology and integrating modern software tools is incredibly important when it comes to advancements in cancer research. By incorporating major technology in the platform and institutionalized systems, it’s possible for greater results to be determined when it comes to medical research.
If physicians have access to tools that are integrated and quickly accessible, it is possible for a lot more information that analyzes critical data to be easily available for science and institutional research at large. Eric Lefkofksy of TempusLabs explains that researchers currently don’t have enough data in order to find large-scale applications and potential opportunities for treatment. There is a great deal of data that is isolated because therapeutic and molecular information is not available at a in a collective data set or pool. Public data sets are very small and can include up to approximately 20,000 patients which is not a large enough sample size to create lasting results of analysis. The future of cancer research will benefit significantly from cross-institutional collaboration in order to achieve the standards set forth in Cancer Moonshot.